The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers by Bartneck M et al.
ORIGINAL RESEARCHThe CCR2D Macrophage Subset Promotes Pathogenic
Angiogenesis for Tumor Vascularization in Fibrotic Livers
Matthias Bartneck,1 Peter L. Schrammen,1 Diana Möckel,2 Olivier Govaere,3 Anke Liepelt,1
Oliver Krenkel,1 Can Ergen,1 Misti Vanette McCain,4 Dirk Eulberg,5 Tom Luedde,1
Christian Trautwein,1 Fabian Kiessling,2 Helen Reeves,4 Twan Lammers,2 and Frank Tacke1
1Department of Medicine III, 2Institute for Experimental Molecular Imaging, Rheinisch-Westfälische Technische Hochschule
Aachen, Aachen, Germany; 3Institute of Cellular Medicine, 4Newcastle Cancer Centre at the Northern Institute for Cancer
Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom; 5NOXXON Pharma AG, Berlin, GermanySUMMARY
Hepatocellular carcinoma typically arises in livers affected
by long-standing chronic injury, persistent inflammation,
and tissue scarring (fibrosis). We herein define in human
samples and in a fibrosis–cancer mouse model a specialized
population of infiltrating inflammatory cells, termed mac-
rophages, that constitute the tumor environment and pro-
vide molecular signals for blood vessel formation to support
tumor growth, termed angiogenesis. Inhibiting the macro-
phage infiltration of fibrotic livers by blocking chemotactic
signals may provide a new therapeutic strategy to suppress
pathogenic angiogenesis.
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC)
typically arises in fibrotic or cirrhotic livers, which are char-
acterized by pathogenic angiogenesis. Myeloid immune cells,
specifically tumor-associated macrophages (TAMs), may
represent potential novel therapeutic targets in HCC, com-
plementing current ablative or immune therapies. However, the
detailed functions of TAM subsets in hepatocarcinogenesis have
remained obscure.
METHODS: TAM subsets were analyzed in-depth in human
HCC samples and a combined fibrosis–HCC mouse model,established by i.p. injection with diethylnitrosamine after birth
and repetitive carbon tetrachloride (CCl4) treatment for 16
weeks. Based on comprehensively phenotyping TAM subsets
(fluorescence-activated cell sorter, transcriptomics) in mice, the
function of CCR2þ TAM was assessed by a pharmacologic
chemokine inhibitor. Angiogenesis was evaluated by contrast-
enhanced micro–computed tomography and histology.
RESULTS:We show that human CCR2þ TAM accumulate at the
highly vascularized HCC border and express the inflammatory
marker S100A9, whereas CD163þ immune-suppressive TAM
accrue in the HCC center. In the fibrosis–cancer mouse model,
we identified 3 major hepatic myeloid cell populations with
distinct messenger RNA profiles, of which CCR2þ TAM partic-
ularly showed activated inflammatory and angiogenic path-
ways. Inhibiting CCR2þ TAM infiltration using a pharmacologic
chemokine CCL2 antagonist in the fibrosis–HCC model signifi-
cantly reduced pathogenic vascularization and hepatic blood
volume, alongside attenuated tumor volume.
CONCLUSIONS: The HCC microenvironment in human patients
and mice is characterized by functionally distinct macrophage
populations, of which the CCR2þ inflammatory TAM subset has
pro-angiogenic properties. Understanding the functional dif-
ferentiation of myeloid cell subsets in chronically inflamed
liver may provide novel opportunities for modulating hepatic
372 Bartneck et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 2macrophages to inhibit tumor-promoting pathogenic angio-
genesis. (Cell Mol Gastroenterol Hepatol 2019;7:371–390;
https://doi.org/10.1016/j.jcmgh.2018.10.007)
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https://doi.org/10.1016/j.jcmgh.2018.10.007Lrelated death, with a dramatically increasing inci-
dence in industrialized countries.1 Hepatocellular carcinoma
(HCC) usually occur in patients with cirrhosis, in which
persistent inflammation, hepatocyte cell death, and
compensatory regeneration, as well as excessive fibrosis
contribute to a tumor-promoting microenvironment.2
Enhanced angiogenesis with the formation of a pathogenic
vasculature is a common feature of liver fibrosis3 and is
considered a key component of a tumor-promoting or
tumor-sustaining stroma.4 We previously showed that
pathogenic angiogenesis in hepatic fibrosis is driven by
liver-infiltrating, monocyte-derived macrophages that are
being recruited to chronically injured livers via the C-C motif
chemokine receptor 2 (CCR2).5 It therefore is conceivable
that modulating hepatic macrophages could effectively
remodel the tumor microenvironment,6,7 which may pre-
vent HCC development or may enhance the efficacy of
chemotherapy, immune checkpoint inhibition, or anti-
angiogenic therapies.8,9
The tumor microenvironment contains multiple myeloid
cell types with overall immune-suppressive functions,
including neutrophils, dendritic cells, and tumor-associated
macrophages (TAMs).10 Analogous to the classification of
Th1 and Th2 T-helper cell subsets, TAMs often are char-
acterized as ‘alternatively activated’ M2 type macrophages
because of their expression of CD163, T-cell suppression,
and release of anti-inflammatory cytokines.11 However,
experimental models of different types of solid tumors
identified heterogeneous subpopulations of TAMs, some of
which also express a ‘classically activated’ inflammatory
M1 signature.12 Nonetheless, a high density of TAMs have
been related consistently to poor patient prognosis in
many types of cancer,13 including observations in human
HCC.14,15 In line with this, high expression of the C-C motif
chemokine ligand 2 (CCL2), the ligand for CCR2, in the
tumor and its surrounding tissue has been linked to poor
survival in a large cohort of patients with HCC,16 indicating
that CCR2þ TAM may promote liver cancer. In experi-
mental animal models of HCC, however, macrophages can
exert protumoral as well as antitumoral functions during
hepatocarcinogenesis.17 For instance, CCR2þ monocyte-
derived macrophages can suppress early tumor formation
by clearing senescent hepatocytes, although they may
promote hepatocarcinogenesis in established tumors.18
Similarly, inhibiting CCR2þ macrophage recruitment
reduced the tumor burden in models of subcutaneous
implantation of hepatoma cells into mice.16,19 In agree-
ment, inhibition of CCL2 by a neutralizing antibody also
reduced the spontaneous development of liver tumors in
microRNA122-deficient mice.20In this study, we set out to dissect the TAM subtypes
involved in HCC progression with a particular focus on
characterizing the role of CCR2þ monocyte-derived TAMs in
the tumor-prone environment of fibrotic livers. We show
that CCR2þ TAMs co-localize with inflammatory markers
and pathogenic vasculature at the tumor border in human
HCC, whereas suppressive CD163þ CCR2- TAMs are found
primarily within tumor nodes. We used a combined mouse
model of endogenous liver cancer, which is initiated by
diethylnitrosamine (DEN) exposure after birth and acceler-
ated by repetitive injections of carbon tetrachloride (CCl4)
causing liver fibrosis. We show that pharmacologic inhibi-
tion of the chemokine CCL2 reduced CCR2þ TAMs, alongside
significantly reduced pathogenic vascularization, hepatic
blood volume, and, subsequently, tumor volume. Detailed
characterization of TAM subsets from the fibrosis–cancer
model identified a functional heterogeneity among 3 major
subsets, with angiogenesis-promoting features in the CCR2þ
TAMs, thereby indicating the potential of targeting macro-
phage subsets to prevent or reduce hepatocarcinogenesis in
patients suffering from liver fibrosis.
Results
CCR2þ TAMs Accumulate in the Stroma of
Human HCC and Co-localize With Pathogenic
Vascularization
The relevance of TAM for the progression of human HCC
has been proposed from studies linking the accumulation of
stromal macrophages,14 activated monocytes,15 and the
expression of the chemoattractant CCL216 to a decreased
survival rate in patients with HCC. Given the heterogeneity
of TAMs in experimental cancer models,21 we first analyzed
TAM subsets in sections of resected human HCC by staining
for the chemokine receptor CCR2, the inflammatory marker
S100 calcium binding protein A9 (S100A9), the anti-
inflammatory marker CD163, and the pan-macrophage
marker CD68 (see Table 1 for patient characteristics).
CCR2þ TAMs significantly accumulated at the interface be-
tween tumor and surrounding tissue, and were found to
infiltrate the epithelial tumor tissue (Figure 1A). The CCR2þ
cells at the tumor border showed a round monocyte-like
morphology, and a substantial fraction of them expressed
S100A9, indicating an inflammatory polarization.22 Fewer
CCR2 or S100A9 expressing TAMs were found at the tumor
center compared with the border, whereas CD163þ and
CD68þ cells were numerous in the center as well and
Table 1.Characterization of the Study Cohort Comprising
Human HCC Patients
Parameters HCC patients
Number, n 10
Sex, male/female, n 8/2
Age, median (range), y 63 (57–79)
Body mass index, median (range), kg/m2 27.8 (20–35)
Type 2 diabetes, n (%) 3 (30)
Cirrhosis, n (%) 9 (90)
Child score, median (range), points 5 (5–10)
Disease etiology
Alcoholic liver disease, n (%) 3 (30)
Nonalcoholic steatohepatitis, n (%) 1 (10)
Viral hepatitis (HBV/HCV), n (%) 5 (50)
Genetic or cryptogenic, n (%) 2 (20)
BCLC stage A/B/C, n (%) A 7 (70)/B 0 (0)/C 3 (30)
HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC,
Barcelona Clinic Liver Cancer.
2019 CCR2+ Macrophages in Tumor Vascularization 373showed a stretched morphology (Figure 1B), in agreement
with a mature, suppressive macrophage subset.23 Statistical
evaluation confirmed that the CCR2þ TAMs were signifi-
cantly enriched at the stroma and HCC borders, similar to
the S100A9þ TAMs. In contrast, the CD163þ as well as the
CD68þ TAMs were more numerous in parenchyma and
distributed more evenly throughout tumor and stroma
areas (Figure 1C). Because these data indicated a specific
accumulation of CCR2þ TAMs at the stroma/tumor-
interface, we also stained for the endothelial marker CD31,
which largely marks pathogenic vessel formation in fibrotic
liver.5 CCR2þ TAMs clearly co-localized with CD31þ endo-
thelial cells in areas of dense vascularization (Figure 1D).
Enlarged views on the different tissue sections clarify
the distinct differences in cell morphology between mac-
rophages in the tumor border (mostly round) (Figure 2A)
and tumor center (stretched) (Figure 2B). Importantly, we
excluded that the infiltration of immune cells was triggered
by the surgical resection because similar numbers of
CCR2þ cells were found in needle biopsy specimens
(Figure 2C).
CCL2 Inhibition Reduces Hepatic Blood Volume
and Tumor-Supporting Pathogenic Angiogenesis
To study the role of CCR2þ TAMs in tumor progression,
we used a mouse model for autochthonous liver cancer in
fibrotic liver, in which multifocal tumor formation was
initiated by DEN and accelerated by fibrosis induction as a
result of repetitive injections of CCl4.
24 Inhibition of the
CCR2-dependent TAMs was achieved by the RNA aptamer-
based inhibitor for CCL2 (CCL2i), mNOX-E36, over 16
weeks, which we have used before in models of chronic liver
injury.5 The vascularization of the liver (and other organs)
was assessed by contrast-enhanced micro–computed to-
mography (m-CT)–based methodology. CCL2 inhibition led
to a remarkable reduction in the vascular bed of the liverand, consequently, the hepatic blood volume, as clearly
visible in 3-dimensional (3D) reconstructions of the in vivo
imaging (Figure 3A, Supplementary Videos 1–5 provide 3D
reconstructed livers). Quantification of the hepatic blood
volume showed that the liver volume remained similar,
whereas the hepatic blood volume was reduced significantly
by pharmacologic CCL2 inhibition (Figure 3B). These ob-
servations were confirmed by high-resolution ex vivo m-CT
scans of tumor-bearing fibrotic livers, by which livers from
DEN-CCl4–treated mice were able to preserve the vascular
structure upon CCL2 inhibition (Figure 3C). Measurement of
CCL2 serum levels confirmed strong target engagement of
the inhibitor by significantly increased CCL2 in serum
(Figure 3D), which consists of inactive CCL2/mNOX-E36
complexes.25 In agreement with reduced hepatic blood
volume, the staining pattern for CD31þ endothelial cells was
partially abrogated in CCL2i-treated mice (Figure 3E), cor-
responding to significantly reduced numbers of hepatic
endothelial cells (Figure 3F). Importantly, CCL2 inhibition
does not affect proliferation of primary hepatic endothelial
cells directly or angiogenic sprouting of blood vessels
in vitro,5 indicating that CCR2þ TAMs promote pathogenic
angiogenesis.Inhibition of CCL2 Affects Tissue Remodeling
and Tumor Volume in the Combined
Fibrosis–Cancer Model
Macroscopic analysis of livers from mice subjected to
the combinedfibrosis–HCCmodel showedthatCCL2 inhibition
led to a slight reduction in the number of hepatic tumors
(Figure 4A). Treatment with CCl4 alone did not induce tumors,
and the inactive control substance (reverse sequence,
revmNOX-E36, revCCL2i) did not affect tumor number
(Figure 4A). Histologic analysis based on H&E staining
showed a less disturbed tissue architecture in the CCL2i-
exposed animals compared with DEN and CCl4 or revCCL2i
(Figure 4B). Staining of collagen I (indicative for fibrosis) and
collagen IV (strongly expressed in liver tumors) showed
reduced extracellular matrix fibers by CCL2 inhibition
(Figure 4C), although these differences did not reach statistical
significance (Figure 4D). Macroscopic evaluation further
showeda tendency toward reduced tumorburden (Figure4D).
Most interestingly, contrast-enhanced m-CT–based eval-
uation of intrahepatic tumors of 2 representative animals
showed that CCL2 inhibition led to tumor nodules with
central necrosis (Figure 5A, Supplementary Videos 6–10
show representative CT scans through the livers), along-
side reduced central tumor perfusion compared with DEN-
CCl4– or revCCL2i-treated mice. This corresponded to an
overall reduced volume of radiologically measured intra-
hepatic tumors (Figure 5B), which was based on 3D re-
constructions of conventional 2-dimensional CT scans
(transversal, coronal, and sagittal) (representative pictures
are shown in Figure 5C). Collectively, these data indicate
that CCR2þ TAMs remodel liver tissue and their inhibition
leads to liver tissue preservation and reduced tumor
progression.
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Figure 1. Hepatic tumor-associated macrophages and colocalization with endothelial cells in human liver cancer.
Human HCC resection specimens were stained for CCR2, S100A9, CD163 (subsets of macrophages), and CD31 (endothelial
cells). (A) Representative sections of human HCC with surrounding noncancerous tissue showing the different localizations of
TAMs. Dashed line indicates border between tumor (Tu) and surrounding tissue (ST). (B) Representative example of TAMs in
tumor center regions. (C) Statistical evaluation of TAM locations in stromal and cancerous regions. (D) Colocalization of CCR2þ
and CD31þ cells at the tumor border. Data represent means ± SD of N ¼ 10. *P < .05, **P < .01, ***P < .001, calculated for
intraregion analysis (HCC or stroma) (1-way analysis of variance). ST, surrounding tissue; Tu, tumor.
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in the Fibrosis–Cancer Model
To link the effects of CCL2 inhibition on tissue remod-
eling, tumor volume, and angiogenesis to specific TAM
populations, we analyzed the hepatic immune cell compo-
sition in the fibrosis–HCC model in peritumoral tissue.
Immunohistochemical staining of the pan-macrophage
marker F4/80 showed a clear increase in hepatic macro-
phages induced by CCl4, DEN-CCl4, and the respective
revCCL2i mice compared with healthy livers. In contrast,
F4/80þ cells were strongly reduced by CCL2i treatment
(Figure 6A and B). When hepatic macrophages wereclassified as CD45þ Ly6G- cells according to their expression
of F4/80 and CD11b by flow cytometry,26 CD11bþF4/80þ
monocyte-derived macrophages (MoMFs) were reduced
significantly by CCL2i, whereas CD11bintF4/80þ Kupffer
cells (KCs) remained unaffected by CCL2 inhibition
(Figure 6B). Because different subsets of myeloid cells,
including neutrophils, are functionally important in the tu-
mor microenvironment, we applied a different flow-
cytometric gating strategy that differentiated CD45þ
CD11bþ myeloid cells further by their expression of Gr1
(Ly6C/G) and major histocompatibility complex class II
(MHCII).27,28 This analysis identified a myeloid infiltrate
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Figure 2. Subpopulations of tumor-associated macrophages in human liver cancer. Human HCC resection specimens
(n ¼ 10) and needle biopsy specimens (n ¼ 8) were stained for CCR2, S100A9, and CD163. (A) Representative sections of
human HCC with surrounding noncancerous tissue showing the different localizations of TAMs. (B) Enlarged view (repre-
sentative example) of TAMs in tumor center regions. (C) Quantifications of CCR2 in needle biopsy specimens (mostly reflecting
tumor center) and resections (separated for HCC center and border, as separated by white dashed lines).
2019 CCR2+ Macrophages in Tumor Vascularization 375containing Ly6Cþ monocytes and Ly6Gþ neutrophils (R1) as
well as 2 populations of TAMs (R2 and R3) (Figure 6C). The
Gr1lowMHCIIhigh TAM population, herein termed TAM1,
contained MoMF and KCs as per a traditional gating strategy
and was reduced upon CCL2 inhibition (R2) (Figure 6C). The
Gr1lowMHCIIlow TAM population, herein termed TAM2,
differed from conventional macrophages in non–tumor-
containing livers and was only slightly affected by CCL2
inhibition (R3) (Figure 6C). The fibrosis–tumor model leads
to a general induction of monocytes in blood and bone
marrow. In contrast, the CCL2i specifically reduced myeloid
populations in the liver, but did not affect blood and bone
marrow monocytes (Figure 6D).
We further analyzed the myeloid cells directly from the
tumor tissue (Figure 6E). Quantifications of the cellular
subsets showed that, compared with the peritumoral tissue,
the MoMF, TAM1, and TAM2 were reduced, whereas the KCs
and myeloid infiltrate (MI) were increased in the tumor
regions. However, the changes induced in the cell pop-
ulations triggered by CCL2i and revCCL2i were similar to
the peritumoral tissue (Figure 6F).
Interestingly, already after 6 weeks of treatment with
CCl4, before tumors became visible (Figure 7A), the myeloidcell populations (Figure 7B), but not the lymphoid cells,
were increased significantly compared with the 16-week
time point (Figure 7C), corroborating the central role of
myeloid cells during fibrogenesis and early stages of tumor
development.CCR2þ TAMs Show an Inflammatory and
Angiogenic Phenotype
To classify the functionality of the TAM subsets in more
detail, we subjected highly purified populations of MI,
TAM1, and TAM2 after fluorescence-activated cell sorting
from livers of the fibrosis–cancer mouse model to Nano-
string (Seattle, WA) arrays including 561 immunology-
related messenger RNA (mRNA) transcripts. The different
myeloid cell subsets significantly differed in their mRNA
expression of typical macrophage markers (summarized in
Figure 8A). Using unbiased gene set enrichment analysis, the
pathways most strongly regulated in the TAM1 subset
included mRNAs involved in angiogenesis signaling and
monocyte differentiation, whereas the MI (which also
express Ccr2) prominently up-regulated mRNAs involved in
antigen processing and presentation (Figure 8B). In detail,
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Figure 3. CCL2 inhibition in a combined fibrosis–HCC model results in reduced hepatic angiogenesis in vivo. Mice
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injection of oil or CCl4. (A) 3D volume renderings of hepatic blood vessels using an iodine-based blood pool contrast agent
(eXIA160XL), resulting in a spatial resolution of 35-mm voxel side length. (B) m-CT–based quantifications of relative hepatic
blood volume and liver volume. (C) High-resolution ex vivo m-CT imaging (after perfusion with Microfil, a lead-containing
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*P < .05 (1-way ANOVA).
376 Bartneck et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 2the MI significantly up-regulated mRNA associated with the
immunologic synapse such as H2-ab1 and Cd83, and highly
up-regulated the pleiotropic marker macrophage migration
inhibitory factor. Key mRNA up-regulated by TAM1 were
inflammatory mediators such as S100a9 and Il1b, but also
Vegfa and matrix metalloproteinase 9 (Mmp9), which are
associated with initiating angiogenesis in carcinogenesis.
TAM2 expressed the Ccl6 chemokine, which is involved in
immune cell recruitment, and nuclear factor-kB inhibitor a
(NfkBia), which negatively regulates the important nuclear
factor-kB pathway that is associated with many inflamma-
tory processes (Figure 8C). These data suggest that each
myeloid subset in liver cancer is involved in specific bio-
logical processes. Interestingly, the CCL2i had a stronger
effect on the TAM1 and TAM2 subsets than on the MI,despite the fact that the MI also express high levels of CCR2,
the ligand of CCL2. In particular, it was noted that the CCL2i-
induced down-regulation of specific markers including
S100a9 and Vegfa were down-regulated by the CCL2i in
TAM1, but up-regulated these in the TAM2 subset by the
CCL2i (Figure 8D).
Detailed analyses illustrate the strong differences in the
expression of mRNA by the different myeloid cells: although
the MI and TAM1 highly expressed Ccr2/Ccl2, the TAM2
expressed very low levels of Ccr2/Ccl2. In addition to strong
Ccr2 and Cd14 expression, another hallmark of the TAM1
subset was high Clec5a expression. Notably, the TAM2
subset expressed many myeloid markers (Ccr2, Ccl2, Il4r,
Cd64) at a very low level (Figure 9A), but showed markers
of a mature, rather immune-suppressive phenotype such as
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Figure 4. Effects of CCL2 inhibition on the progression of liver cancer. Mice received vehicle (corn oil) and were left either
untreated for 24 weeks, or received 16 weeks of twice-weekly injections of CCl4; received DEN at 14 days of age and were
challenged with CCl4 for 16 weeks; were treated with DEN and CCl4 and received CCL2i mNOXE36 3 times/wk subcutane-
ously; or received DEN, CCl4, and revCCL2i. Mice were killed 48 hours after the last injection of oil or CCl4. (A) Representative
macroscopic analysis of the different conditions (valid for all subfigures). (B) H&E staining. (C) Immunofluorescence staining of
collagen I and IV. (D) Quantification of the collagen I and IV area fraction and of the cumulative tumor diameter from mac-
roscopy. Data represent means ± SD of N ¼ 6.
2019 CCR2+ Macrophages in Tumor Vascularization 377Mannose receptor-1 (Mrc1) or Arginase-1 (Arg1) (Figure 9A).
Venn diagrams reflect summaries on the mRNA regulation
in the different myeloid subsets and the effects of the CCL2i
(Figure 9B and C). Only very few changes occurred in the MI
by the CCL2i, but unexpectedly, some mRNAs in TAM2 also
were affected (Tables 2 and 3). However, hierarchical
clustering analysis (based on the similarity of mRNA
expression) identified the most striking changes induced byCCL2i to the TAM1 populations (Figure 10). Key pathways
of TAM2 cells that were affected by CCL2i related to in-
flammatory pathways (Figure 11). These data indicate that
CCL2 inhibition promotes characteristic changes in the
TAM2 population, too, which could be a compensatory
response of TAM2 caused by reduced TAM1 cells or a direct
result of CCL2 inhibition (eg, by reducing the cellular pre-
cursors of TAM2 from the TAM1 population).
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age and were challenged with CCl4 for 16 weeks; treated with DEN and CCl4 and received CCL2i mNOXE36 3 times/wk
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Tumor-associated macrophages increasingly are recog-
nized as emerging targets to improve anticancer therapies.29
For instance, the reprogramming of TAM toward inflam-
matory cells via CD40 stimulation and colony-stimulating
factor 1 receptor inhibition boosted antitumor immunityin mice.30,31 Such findings support the notion that myeloid
targeting interventions have the potential to augment cur-
rent cytoreductive approaches such as chemotherapy, ra-
diation, or local ablation, as well as to complement immune
checkpoint-inhibitor therapies in many solid tumors.29 HCCs
arise almost exclusively in chronically inflamed and fibrotic
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Figure 7. Myeloid and lymphoid cells at early stages of cancer development. Mice at 14 days of age received DEN and
twice-weekly injections of CCl4 for 6 weeks. In addition, mice were treated with CCL2i mNOXE36 or revCCL2i 3 times/wk
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roles in sustaining inflammation, promoting disease pro-
gression, and provoking tissue remodeling.17 Although
myeloid cells in livers with established tumors typically are
immune-suppressive and associated with a poor prog-
nosis,21 the characteristic sequence of long-standing chronic
liver disease, fibrosis, and, ultimately, HCC development,
offers the potential for chemopreventive approaches by
modulating hepatic macrophages.2,7 Hepatic macrophages,
however, show a remarkable heterogeneity. The classic
KCs derive from local precursors, whereas a large fraction of
macrophages in inflamed liver are descendants ofFigure 6. (See previous page). Analysis of hepatic tumor–as
were left either untreated for 24 weeks; received 16 weeks of tw
and were challenged with CCl4 for 16 weeks; were treated wit
subcutaneously; or received DEN, CCl4, and revCCL2i. Mice w
Immunohistochemical staining of F4/80þ hepatic macrophages
macrophage subsets (pregated on CD45þ and subsequently Ly
as CD11bintF4/80þ, and quantifications of the subsets in 3 dif
circle) and KC (green circle) to subsets of TAMs (pregated as CD
myeloid infiltrate (composed of monocytes and neutrophils) sc
Gr1lowMHCIIhigh, and anti-inflammatory TAM2, which are Gr1low
blood and bone marrow. (E) Selection of peritumoral (blue outlin
quantifications of the myeloid subsets in the tumor tissue. Data
analysis of variance).tissue-infiltrating monocytes of bone marrow origin.17 In
the current work, we hypothesized that targeting the
monocyte-derived macrophage fraction by inhibiting the
chemokine CCL2 in a combined liver fibrosis–cancer model
in mice would modify progression of primary liver tumors.
In line with previous reports from patient cohorts with
HCC,14–16 we observed CCR2þ macrophages at the interface
of tumors and surrounding hepatic tissue in HCC resections.
However, these macrophages expressed the inflammatory
marker S100A9 rather than CD163, indicating that these
TAMs do not belong to the typical suppressive M2-like
myeloid population described in human HCC. Strikingly,sociated myeloid cells. Mice received vehicle (corn oil) and
ice-weekly injections of CCl4; received DEN at 14 days of age
h DEN and CCl4 and received CCL2i mNOXE36 3 times/wk
ere killed 48 hours after the last injection of oil or CCl4. (A)
in peritumoral regions. (B) Gating of the hepatic peritumoral
6G-), MoMFs identified as CD11bþF4/80þ and KCs identified
ferent experiments. (C) Allocation of peritumoral MoMF (red
45þCD11bþ) by back-gating analysis. Myeloid cells include a
oring Gr1highMHCIIlow/int, proinflammatory TAM1 expressing
MHCIIlow. (D) Effects on CD45þCD11bþLy6G- monocytes in
e) and tumoral tissue (red outline) for flow cytometry, and (F)
represent means ± SD of N ¼ 6. *P < .05, **P < .01 (1-way
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382 Bartneck et al Cellular and Molecular Gastroenterology and Hepatology Vol. 7, No. 2these CCR2þ TAMs co-localized with newly formed blood
vessels, as identified by (pathogenic) CD31 expression. In a
combined liver fibrosis–cancer model in mice, pharmaco-
logic inhibition of monocyte recruitment via CCL2 strongly
suppressed pathogenic angiogenesis. These data are well in
agreement with earlier work showing a critical role of
CCR2þ monocyte-derived macrophages for angiogenesis in
liver fibrosis.5
Angiogenesis is considered a hallmark of cancer,32 but
also is linked to fibrosis progression in the liver.4 Tumor-
associated macrophages may promote pathogenic angio-
genesis in many types of cancer,33,34 but conflicting data
exist on the exact phenotype of angiogenesis-promoting
macrophages. In vitro as well as after implantation into
mice, M2-polarized macrophages had a higher angiogenic
potential than their M1-polarized counterparts.35 In a
similar direction, CD163-expressing macrophages were
associated with plaque-related angiogenesis in human and
murine atherosclerosis,36 and repolarization of TAMs to-
ward an M1-phenotype normalized aberrant blood vessels
in a murine melanoma model.37 Our data corroborate that
the traditional M1/M2 paradigm is not suitable to appre-
hend the heterogeneity and functional diversity of macro-
phages in the environment of a chronically injured liver. By
comparing 3 major myeloid cell compartments from tumor-
bearing fibrotic livers, based on surface characteristics
proposed for TAMs,28 it became apparent that functional
pathways related to inflammation, angiogenesis, and im-
munity were regulated differentially between the 3 subsets.
Although the CCR2-dependent TAM1 population activated
pathways of angiogenesis as well as specific inflammatory
markers (eg, S100a9 or Il1b), their antigen processing and
presentation abilities appeared reduced, supporting the
notion that TAM1 do not bear strong immunogenic and
T-cell regulating properties. On the other hand, the CCR2-
TAM2 population showed many characteristics of immune-
suppressive macrophages. Consequently, pharmacologic
inhibition of CCL2, which mainly suppressed the numbers of
CCR2þ TAM1 in the fibrosis–cancer model, inhibited path-
ogenic tumor vascularization in vivo.
Interestingly, the pharmacologic inhibition of CCL2 not
only affected CCR2þ TAM1, but also induced changes in the
CCR2- TAM2 population. For instance, TAM2 up-regulated
S100a9, an inflammatory molecule related to NK cell acti-
vation in tumors,38 in tumor-bearing mice treated with the
CCL2 inhibitor. These data imply a remarkable plasticity of
the hepatic myeloid cells, including compensatory activation
when suppressing distinct subsets. In studies based on 4T1
tumor cell line implantation in mice, TAM2 were shown toFigure 8. (See previous page). Analysis of subpopulations of
cell sorting and mRNA profiling. Mice received vehicle (corn
weeks of twice-weekly injections of CCl4; received DEN at 14 d
treated with DEN and CCl4 and received CCL2i mNOXE36 3 tim
Mice were killed 48 hours after the last injection of oil or CCl4. (A
composed of monocytes and neutrophils scoring Gr1highMHCI
inflammatory TAM2, which are Gr1lowMHCIIlow. (B) Unbiased
TAMs. (C) Characteristic mRNA expressed by TAM1. (D) Chang
Data represent means ± SD of 2 independent experiments. *Poriginate from TAM1, which were derived from infiltrating
monocytes.28 The close relationship between myeloid cell
subsets in the liver and their partial functional redundancy
may have major implications for chemopreventive or ther-
apeutic strategies.7 As shown in our study, inhibiting CCL2-
dependent macrophage accumulation affected fibrosis and
angiogenesis in the DEN-CCl4 model, and lead to reduced
tumors sizes. The mouse model of multifocal autochthonous
HCC development in a fibrotic liver investigated in our study
substantially differed from the simple injection of hepatoma
cells, in which CCR2-targeting approaches were reported to
convey beneficial effects on tumor burden.16,19 It is note-
worthy that the CCR2/CCR5 inhibitor cenicriviroc is
currently under phase 3 clinical investigation in patients
with nonalcoholic steatohepatitis and advanced fibrosis,39
who represent a high-risk group for liver cancer. Based on
the observation from our study, the immunologic changes
induced by CCL2 inhibition already are present early in the
fibrosis–cancer model (after 6 weeks of CCl4, before tumors
are apparent), beneficial effects of CCR2/CCR5 or CCL2 in-
hibition on tissue remodeling and angiogenesis could be
anticipated in these patients. The clear link between CCR2þ
macrophages and pathogenic tumor vascularization sup-
ports the exploration of combination therapies (eg,
combining CCR2 or CCL2 inhibition with conventional HCC
treatment modalities), and with novel programmed cell
death protein 1-directed immunotherapies.Material and Methods
Human Liver Cancer Specimens
Formalin-fixed, paraffin-embedded liver samples from
HCC patients (resection specimens, n ¼ 10; diagnostic
needle biopsy specimens, n ¼ 8) were analyzed as approved
by the Newcastle and North Tyneside Regional Ethics
Committee, the Newcastle Academic Health Partners Bio-
resource, and the Newcastle upon Tyne National Health
Service Foundation Trust Research and Development
department (10/H0906/41; Newcastle Academic Health
Partners Bioresource project 48; REC 12/NE/0395; R&D
6579; and Human Tissue Act license 12534). Informed
consent was obtained from all patients. Detailed information
on patient characteristics is shown in Table 1. Sections were
stained using antibodies directed against human CCR2
(ab176390; Abcam, Cambridge, UK), S100A9 (ab63818;
Abcam), CD163 (760-4437, MRQ-26; Ventana Medical Sys-
tems, Inc, Tucson, AZ), CD68 (790-2931; Ventana), and
CD31 (760-4378, JC70; Ventana). CCR2 and S100A9 stain-
ings were performed manually using Envision Flexþ reagenthepatic tumor–associated myeloid cell populations using
oil) and were left either untreated for 24 weeks; received 16
ays of age and were challenged with CCl4 for 16 weeks; were
es/wk subcutaneously; or received DEN, CCl4, and revCCL2i.
) Gating strategy for subsets of peritumoral myeloid cells: a MI
Ilow/int, proinflammatory TAM1 being Gr1lowMHCIIhigh, or anti-
quantitative analysis of inflammatory mRNA expression of
es in the mRNA profiles of TAM subsets induced by CCL2i.
< .05 (1-way analysis of variance). FDR, false discovery rate.
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Figure 9. Expression of mRNA by TAM subsets and Venn diagram. Mice at 14 days of age received DEN and twice-weekly
injections of CCl4 for 16 weeks. Peritumoral hepatic myeloid cells were isolated and subjected to quantitative analysis of
mRNA expression (Nanostring immunology kit). (A) Changes are shown in selected mRNA of the 3 subsets of myeloid in-
filtrators, defined as Gr1þMHCIIlow/int, TAM1 as Gr1lowMHCIIhigh, and TAM2, which were classified as Gr1lowMHCIIlow. The MI
was defined as Gr1þMHCIIlow/int, TAM1 as Gr1lowMHCIIhigh, and TAM2 as Gr1lowMHCIIlow. Three-fold changes in mean gene
expression were used to characterize the subsets. (B) Summary of mRNA expression by the different subsets and (C) of the
effects of the CCL2i. Data in panel A represent means ± SD. *P < .05, **P < .01, calculated against DEN–CCl4 disease control
(1-way analysis of variance).
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Table 2.List of mRNA Up-regulated by the TAM2 Subset
(Myeloid Cells Scoring Gr1lowMHCIIlow), but No
Longer Up-regulated Upon Treatment With the
CCL2i Subjected for Biocarta-Based Gene Group
Analysis
Gene
symbol Full name
Abcb1a ATP-binding cassette, subfamily B (MDR/TAP),
member 1A
Btnl1 Butyrophilin-like 1
C2 Complement component 2 (within H-2S)
C4bp Complement component 4 binding protein
C7 Complement component 7
C8b Complement component 8, b polypeptide
Ccl26 Chemokine (C-C motif) ligand 26
Ccr6 Chemokine (C-C motif) receptor 6
Cd209g CD209g antigen
Cd27 CD27 antigen
Cd5 CD5 antigen
Cd53 CD53 antigen
Cd6 CD6 antigen
Cd96 CD96 antigen
Csf3r Colony stimulating factor 3 receptor (granulocyte)
Cxcl11 Chemokine (C-X-C motif) ligand 11
Cxcr1 Chemokine (C-X-C motif) receptor 1
Cxcr2 Chemokine (C-X-C motif) receptor 2
Eomes Eomesodermin
Fasl Fas ligand (TNF superfamily, member 6)
Folr4 IZUMO1 receptor, JUNO
Foxp3 Forkhead box P3
Frmpd4 FERM and PDZ domain containing 4
Gp1bb Glycoprotein Ib, b polypeptide
Gzma Granzyme A
H2-Q10 Histocompatibility 2, Q region locus 10
Icam4 Intercellular adhesion molecule 4, Landsteiner–Wiener
blood group
Icam5 Intercellular adhesion molecule 5, telencephalin
Ifitm1 Interferon-induced transmembrane protein 1
Ifna1 Interferon a1
Il17a Interleukin 17A
Il18r1 Interleukin 18 receptor 1
Il18rap Interleukin 18 receptor accessory protein
Il1b Interleukin 1b
Il1r1 Interleukin 1 receptor, type I
Il1r2 Interleukin 1 receptor, type II
Il1rap Interleukin 1 receptor accessory protein
Il21 Interleukin 21
Il22 Interleukin 22
Il22ra2 Interleukin 22 receptor, a 2
Il23a Interleukin 23, a subunit p19
Il2ra Interleukin 2 receptor, a chain
Il3 Interleukin 3
Il33 Interleukin 3
Table 2.Continued
Gene
symbol Full name
Il9 Interleukin 9
Itln1 Intelectin 1 (galactofuranose binding)
Kir3dl1 Killer cell immunoglobulin-like receptor, 3 domains,
long cytoplasmic tail, 1
Klra21 Killer cell lectin-like receptor subfamily A, member 21
Klra5 Killer cell lectin-like receptor, subfamily A, member 5
Klra6 Killer cell lectin-like receptor, subfamily A, member 6
Klra8 Killer cell lectin-like receptor, subfamily A, member 8
Lef1 Lymphoid enhancer binding factor 1
Masp1 Mannan-binding lectin serine peptidase 1
Masp2 Mannan-binding lectin serine peptidase 2
Pla2g2e Phospholipase A2, group IIE
Psmb11 Proteasome (prosome, macropain) subunit, b type, 11
Rag2 Recombination activating gene 2
S100a8 S100 calcium binding protein A8 (calgranulin A)
S100a9 S100 calcium binding protein A9 (calgranulin B)
Sele Selectin, endothelial cell
Tnfrsf9 Tumor necrosis factor receptor superfamily, member 9
Tnfsf15 Tumor necrosis factor (ligand) superfamily, member 15
Trem1 Triggering receptor expressed on myeloid cells 1
Xcl1 Chemokine (C motif) ligand 1
NOTE. Mice at 14 days of age received DEN and twice-
weekly injections of CCl4 for 16 weeks. In addition, mice
were treated with CCL2i mNOXE36 or control inhibitor
(revCCL2i) 3 times/wk subcutaneously. Peritumoral hepatic
myeloid cells were isolated and subjected to quantitative
analysis of mRNA expression (Nanostring immunology kit).
ATP, adenosine triphosphate; IZUMO1, Izumo sperm-egg
fusion 1; JUNO, folate receptor 4, folate receptor delta or
IZUMO1R; MDR, multidrug resistance; TNF, tumor necrosis
factor.
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were performed on the Benchmark Ultra (Ventana). The tu-
mor border was defined as HCC cells adjacent to the tumor
capsule and/or the non-neoplastic surrounding tissue, visible
within a 200 magnification field. On a tissue slide, an area
was considered as the center of the HCC when no tumor
capsule or surrounding tissue could be observed using 50
magnification. Stroma was defined as fibrous tissue either
within the tumor or at the border. Immunopositive cells were
quantified in 3 high-power fields at 400 magnification.
Mice
C57BL6/J wild-type mice were housed in a specific
pathogen-free environment. All experiments were
approved by the appropriate authorities according to
German legal requirements (Landesamt für Natur, Umwelt
und Verbraucherschutz Nordrhein-Westfalen, Reckling-
hausen, Germany). Reporting of animal studies is based on
the Animal Research: Reporting of In Vivo Experiments
guidelines. All mice were analyzed in a blinded and ano-
nymized fashion.
Table 3.List of mRNA Down-regulated by the TAM2 Subset
(Myeloid Cells Scoring Gr1lowMHCIIlow) After
Treatment With the CCL2 Inhibitor Subjected for
Biocarta-Based Gene Group Analysis
Gene
symbol Full name
Aire Autoimmune regulator (autoimmune
polyendocrinopathy candidiasis ectodermal
dystrophy)
Atm Ataxia telangiectasia mutated
Blnk B-cell linker
C1ra Complement component 1, r subcomponent A
C1s Complement component 1s
C2 Complement component 2 (within H-2S)
C4bp Complement component 4 binding protein
C6 Complement component 6
C7 Complement component 7
C9 Complement component 9
Ccl22 Chemokine (C-C motif) ligand 22
Ccl26 Chemokine (C-C motif) ligand 26
Ccl8 Chemokine (C-C motif) ligand 8
Ccr6 Chemokine (C-C motif) receptor 6
Ccr7 Chemokine (C-C motif) receptor 7
Ccr9 Chemokine (C-C motif) receptor 9
Ccrl1 C-C chemokine receptor type 11
Cd163 CD163 antigen
Cd19 CD19 antigen
Cd1d1 CD1d1 antigen
Cd209g CD209g antigen
Cd22 CD22 antigen
Cd247 CD247 antigen
Cd28 CD28 antigen
Cd34 CD34 antigen
Cd3d CD3 antigen, d polypeptide
Cd4 CD4 antigen
Cd40lg CD40 ligand
Cd7 CD7 antigen
Cd83 CD83 antigen
Cd8a CD8 antigen, a chain
Cd96 CD96 antigen
Cdh5 Cadherin 5
Cfd Complement factor D (adipsin)
Cish Cytokine inducible SH2-containing protein
Ctla4 Cytotoxic T-lymphocyte–associated protein 4
Cxcl1 Chemokine (C-X-C motif) ligand 1
Cxcl12 Chemokine (C-X-C motif) ligand 12
Cxcl15 Chemokine (C-X-C motif) ligand 15
Defb1 Defensin b 1
Eomes Eomesodermin
Fasl Fas ligand (TNF superfamily, member 6)
Fcer1a Fc receptor, IgE, high-affinity I, a polypeptide
Foxp3 Forkhead box P3
Gata3 GATA binding protein 3
Gp1bb Glycoprotein Ib, b polypeptide
Table 3.Continued
Gene
symbol Full name
Gpr44 Prostaglandin D2 receptor 2
H2-Ob Histocompatibility 2, O region b locus
H60a Histocompatibility 60a
Hamp Hepcidin antimicrobial peptide
Hcst Hematopoietic cell signal transducer
Icam5 Intercellular adhesion molecule 5, telencephalin
Icos Inducible T-cell co-stimulator
Ifna1 Interferon a 1
Ikzf2 IKAROS family zinc finger 2
Ikzf3 IKAROS family zinc finger 3
Ikzf4 IKAROS family zinc finger 4
Il10 Interleukin 10
Il12a Interleukin 12a
Il12rb1 Interleukin 12 receptor, b 1
Il12rb2 Interleukin 12 receptor, b 2
Il13 Interleukin 13
Il17a Interleukin 17A
Il17b Interleukin 17B
Il17f Interleukin 17F
Il1a Interleukin 1 a
Il1r1 Interleukin 1 receptor, type I
Il1rl1 Interleukin 1 receptor-like 1
Il21 Interleukin 21
Il23a Interleukin 23, a subunit p19
Il28a Interferon l 2
Il2ra Interleukin 2 receptor, a chain
Il4 Interleukin 4
Il7r Interleukin 7 receptor
Itga2b Integrin a 2b
Itga6 Integrin a 6
Itgax Integrin a X
Itln1 Intelectin 1 (galactofuranose binding)
Kir3dl1 Killer cell immunoglobulin-like receptor, 3 domains,
long cytoplasmic tail, 1
Kit Kit oncogene
Klra21 Killer cell lectin-like receptor subfamily A, member 21
Klra5 Killer cell lectin-like receptor, subfamily A, member 5
Klrc1 Killer cell lectin-like receptor subfamily C, member 1
Klrc2 Killer cell lectin-like receptor subfamily C, member 2
Klrk1 Killer cell lectin-like receptor subfamily K, member 1
Lilra5 Leukocyte immunoglobulin-like receptor, subfamily A
(with TM domain), member 5
Ltb4r2 Leukotriene B4 receptor 2
Marco Macrophage receptor with collagenous structure
Masp1 Mannan-binding lectin serine peptidase 1
Masp2 Mannan-binding lectin serine peptidase 2
Ms4a1 Membrane-spanning 4-domains, subfamily A, member
1
Nos2 Nitric oxide synthase 2, inducible
Nox1 NADPH oxidase 1
Nox4 NADPH oxidase 4
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Table 3.Continued
Gene
symbol Full name
Pdcd1 Programmed cell death 1
Pdgfb Platelet-derived growth factor, B polypeptide
Pdgfrb Platelet-derived growth factor receptor,
b polypeptide
Pecam1 Platelet/endothelial cell adhesion molecule 1
Pigr Polymeric immunoglobulin receptor
Pla2g2a Phospholipase A2, group IIA (platelets, synovial fluid)
Pparg Peroxisome proliferator activated receptor g
Prf1 Perforin 1 (pore-forming protein)
Prim1 DNA primase, p49 subunit
Psmb11 Proteasome (prosome, macropain) subunit,
b type, 11
Ptk2 PTK2 protein tyrosine kinase 2
Rag1 Recombination activating gene 1
Rorc RAR-related orphan receptor g
Runx3 Runt-related transcription factor 3
Sele Selectin, endothelial cell
Sh2d1a SH2 domain containing 1A
Slamf7 SLAM family member 7
Src Rous sarcoma oncogene
Tbx21 T-box 21
Tcf7 Transcription factor 7, T-cell specific
Tfrc Transferrin receptor
Tgfb2 Transforming growth factor, b
Thy1 Thymus cell antigen 1, q
Tigit T-cell immunoreceptor with Ig and ITIM domains
Tlr3 Toll-like receptor 3
Tnfaip3 Tumor necrosis factor, a-induced protein 3
Tnfrsf13c Tumor necrosis factor receptor superfamily, member
13c
Tnfrsf17 Tumor necrosis factor receptor superfamily, member 17
Tnfrsf9 Tumor necrosis factor receptor superfamily, member 9
Tnfsf10 Tumor necrosis factor (ligand) superfamily, member 10
Tnfsf11 Tumor necrosis factor (ligand) superfamily, member 11
Tnfsf14 Tumor necrosis factor (ligand) superfamily, member 14
Tnfsf15 Tumor necrosis factor (ligand) superfamily, member 15
Tnfsf8 Tumor necrosis factor (ligand) superfamily, member 8
Xcl1 Chemokine (C motif) ligand 1
Xcr1 Chemokine (C motif) receptor 1
Zap70 Z-chain (TCR)–associated protein kinase
NOTE. Mice at 14 days of age received DEN and twice-
weekly injections of CCl4 for 16 weeks. In addition, mice
were treated with CCL2i mNOXE36 or control inhibitor
(revCCL2i) 3 times/wk subcutaneously. Peritumoral hepatic
myeloid cells were isolated and subjected to quantitative
analysis of mRNA expression (Nanostring immunology kit).
GATA, glutaminyl-tRNA synthase; ITIM, immunoreceptor
tyrosine-based inhibition motif; NADPH, Nicotinamide
adenine dinucleotide phosphate; PTK2, protein tyrosine ki-
nase 2; RAR, retinoic acid receptor; SH2, Src Homology 2;
SLAM, signaling lymphocytic activation molecule; TCR,
T-cell receptor; TM, transmembrane; TNF, tumor necrosis
factor.
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The RNA-aptamer (Spiegelmer) mNOX-E36 (abbreviated
as CCL2i in this study), which specifically binds to murine
CCL2, was kindly provided by NOXXON Pharma AG (Berlin,
Germany). This 50-nucleotide L-RNA oligonucleotide (5’-
GGCGACAUUGGUUGGGCAUGAGGCGAGGCCCUUUGAUGAAUCCG
CGGCCA-3’) inhibits the infiltration of CCR2-dependent
monocytes and macrophages, as shown earlier.5 A control
molecule with reverse nucleotide sequence was used
as inactive control Spiegelmer, termed rev-mNOX-E36
(revCCL2i). The oligonucleotide part of both, the active
drug and the control molecule, is linked covalently with 40-
kilodalton polyethylene glycol at the 3’-end to prevent rapid
renal elimination. The compounds were injected subcuta-
neously at a dose of 20 mg/kg body weight (diluted in 5%
glucose solution) 3 times/wk. All mNOX-E36 (CCL2i) and
revmNOX-E36 (revCCL2i) doses and concentrations refer to
the oligonucleotide part of the molecules.
Liver Fibrosis–Cancer Model
Multifocal liver cancer development was induced by the
carcinogen DEN, which was administered intraperitoneally
into mice 14 days postpartum at 25 mg/kg body weight.40
Starting at the age of 8 weeks (6 weeks after DEN expo-
sure), chronic liver injury was induced using repetitive
intraperitoneal CCl4 (Merck, Darmstadt, Germany) applica-
tions twice weekly for 16 weeks. CCl4 (Merck) was mixed
with corn oil at a dose of 0.6 mL/kg body weight. Mice were
killed 48 hours after the last injection of CCl4 or corn oil
(vehicle). CCL2 was inhibited using the CCL2i (or revCCL2i)
over the whole 16-week period.
m-CT
Mice were anesthetized with 1.5% isoflurane in
oxygen-enriched air and received 100 mL eXIA160XL
intravenously (Binitio Biomedical, Ottawa, Ontario, Can-
ada). Animals were scanned via a dual-energy scan at 41
and 65 kV (at 0.5 and 1 mA), obtaining 2880 projections
sized 1032  1024 over 6 minutes. A Feldkamp-type
reconstruction algorithm was applied with a voxel size of
35  35  35 mm3, including ring artefact correction.
Visualization of reconstructed data was performed with
Imalytics (Aachen, NRW, Germany) Preclinical software.41
The relative blood volume was determined as published
earlier,5 and liver and tumor volumes were quantified on
cross-sectional images in transversal, coronal, and sagittal
planes.
Ex Vivo m-CT
Mice were perfused intracardially with Microfil (Flow
Tech, Carver, MA), a lead-containing silicone rubber CT
contrast agent for high-resolution 3D investigation of the
microarchitecture of blood vessels in the liver. Microfil re-
places the blood volume and polymerizes 20 minutes after
application, resulting in vascular casting. The liver was
excised, formalin-fixed, and scanned using a high-resolution
SkyScan 1272 m-CT system (SkyScan, Kontich, Belgium)
as published earlier.5 After 3D volume rendering of
reconstructed high-resolution m-CT data sets, 3D
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Figure 10. Hierarchical
clustering analysis of
gene expression of
tumor-associated mac-
rophages. Mice at 14
days of age received DEN
and twice-weekly in-
jections of CCl4 for 16
weeks. In addition, mice
were treated with CCL2i
mNOXE36 or control in-
hibitor revCCL2i 3 times/
wk subcutaneously. Peri-
tumoral hepatic myeloid
cells were isolated and
subjected to quantitative
analysis of mRNA expres-
sion (Nanostring immu-
nology kit). (A) Changes
are shown in selected
mRNA of the 3 MI
subsets, defined as
Gr1þMHCIIlow/int, TAM1 as
Gr1lowMHCIIhigh, and TAM2,
which were analyzed
as Gr1lowMHCIIlow. (B)
Enlarged view of the most
differentially expressed
mRNA.
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automatically, using Imalytics Preclinical software.41
Cell Isolation and Sorting
Single-cell suspensions of livers were generated by
mincing the organ into small pieces less than 1 mm and 30
minutes of digestion with collagenase type IV (Worthington,
Lakewood, NJ). Right ventricle blood was subjected to red
blood cell lysis using Pharm Lyse (Becton Dickinson,
Franklin Lakes, NJ), filtered using a 70-mm mesh, and
stained for flow cytometry using CD45, CD11b, Ly6G, Gr1,
F4/80, and MHCII (all BD Biosciences). Count beads (BD)
were added to single-cell suspensions to determine absolute
cell numbers in different organs.Gene Expression Profiling of Tumor-Associated
Macrophage Subsets
Leukocytes were isolated from tumors as described
earlier, and CD11bþ leukocytes were purified using
magnetic-assisted cell sorting (Miltenyi Biotec, Bergisch,
Gladbach, Germany). To further increase purity for sorting
using a BD Aria-II, lineage staining was performed using a
collection of common lymphoid cells (CD4, CD8, B220, and
NK1.1; all BD Biosciences). In each NanoString assay, 20,000
sorted cells were analyzed. Housekeeping mRNA was used
to normalize data and to generate transcript counts. Dif-
ferential gene expression was calculated using the R pack-
age DESeq2. A log2 fold change threshold 2 and an
adjusted P value of .01 for comparison of TAM populations
TAM2 + CCL2i vs. TAM2
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Figure 11. Analysis of the
effects of CCL2 inhibition
on the mRNA expression
of anti-inflammatory he-
patic tumor–associated
macrophages. Mice at
14 days of age received
DEN and twice-weekly in-
jections of CCl4 for 16
weeks. In addition, mice
were treated with CCL2i
mNOXE36 or control in-
hibitor (revCCL2i) 3 times/
wk subcutaneously. Peri-
tumoral hepatic myeloid
cells were isolated and
subjected to quantitative
analysis of mRNA expres-
sion (Nanostring immu-
nology kit). (A) Unbiased
clustered gene enrichment
maps for analysis of the
effects of CCL2 inhibition
on the Gr1lowMHCIIlow
TAM2. (B) Changes in
selected mRNA in the
TAM2 subset.
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untreated TAM was used. Gene set enrichment analysis was
performed using the Cytoscape plug-in BinGO,42 and the
plugin Enrichment Map was used (P < .05, false discovery
rate Q-value < 0.25, and a similarity with a Jaccard coeffi-
cient cut-off value of 0.5. Functional annotations of were
performed using Gene Ontology and Biocarta from the
Database for Annotation, Visualization and Integrated
Discovery database.43 GO and Biocarta pathway terms then
were analyzed for their frequency in the 2 gene sets. Three-
fold expression was used for the Venn diagrams and
hierarchical clustering analysis was based on the mean
value of all experiments.Statistical Analysis
All data are presented as means ± SD. Differences be-
tween groups were assessed using the appropriate statisti-
cal tests (GraphPad Prism 5, LaJolla, CA).References
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